- Recurrent BMPR2 missense variant c.1126G>A (p.Glu376Lys) found in six individuals with autism spectrum disorder and global developmental delay, de novo in at least five.
- Functional studies in Drosophila show the variant is gain-of-function, ligand independent yet type-1 BMP receptor dependent, and hypermorphic, suppressible by BMPR2 inhibitors.
- Neuronal or glial expression of p.Glu376Lys in flies causes neurodevelopmental defects, implicating ectopic BMP activation across neural cell types in human phenotypes.
Am J Hum Genet. 2026 Sep 21:S0002-9297(26)00341-1. doi: 10.1016/j.ajhg.2026.08.019. Online ahead of print.
ABSTRACT
Bone morphogenetic protein receptor type 2 (BMPR2) encodes an evolutionarily conserved serine/threonine kinase that phosphorylates type-1 BMP receptors to mediate intercellular communication upon ligand binding. Loss-of-function variants in BMPR2 are known to cause pulmonary arterial hypertension and other cardiovascular disorders. Here, we report a rare recurrent missense variant in BMPR2 (c.1126G>A [GenBank: NM_001204] [p.Glu376Lys]) identified in six individuals, who all present with neurodevelopmental phenotypes including autism spectrum disorder and global developmental delay. Trio analysis demonstrates de novo occurrence of this variant in at least five of the individuals. Using the fruit fly Drosophila melanogaster, we show that this variant behaves as a gain-of-function allele that acts in a ligand-independent but type-1 BMP receptor-dependent manner. BMPR2-specific inhibitors suppress excessive BMP activation induced by p.Glu376Lys variant expression in Drosophila, demonstrating its hypermorphic property. Finally, we show that this variant causes neurodevelopmental defects in flies when expressed in neurons or glial cells. Given that BMPR2 is expressed in various neural cell types in the human brain, ectopic activation of BMP signaling in multiple cell types is likely to contribute to the neurodevelopmental phenotypes observed in the probands.
PMID:42767215 | DOI:10.1016/j.ajhg.2026.08.019
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

